| 產品名稱 |
Rotavirus reassortant |
| 商品貨號 |
B163294 |
| Classification |
Reoviridae, Rotavirus |
| Agent |
Rotavirus reassortant |
| Strain |
WC3:2-5, R574(9) |
| Applications |
vaccine production |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen |
| Storage Conditions |
-70°C |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Comments |
This strain possesses neutralization antigen phenotype of both serotype 1 rotavirus and bovine (serotype 6) rotavirus. Gene from strain WI79 is from a human infant. Other genes are from bovine rotavirus WC3. -70C |
| Effect on Host |
Yes, in vitro effects: Vague CPE appears as cell rounding and clumping with cell detachment in 7 to 10 days. Vague CPE appears as cell rounding and clumping with cell detachment in 7 to 10 days. |
| Recommended Host |
MA-104 cells (ATCC CRL-2378) Host of Choice: MA-104 (CRL-2378) Host Range: MA-104, BSC-1, CV-1, and primary primate kidney cells MA-104 cells (ATCC CRL-2378); CV-1 cells (ATCC CCL-70); BS-C-1 cells (ATCC CCL-26); primary primate kidney cells |
| Growth Conditions |
Duration: 3-10 days at 37C, with rocking apparatus |
| Cryopreservation |
Storage temperature: -70C |
| Name of Depositor |
Wistar Institute |
| U.S. Patent |
|
| U.S. Patent Number |
|
| Special Collection |
NCRR Contract |
| References |
Clark HF, et al. Rotavirus reassortant vaccine. US Patent 5,626,851 dated May 6 1997
Wistar Institute, personal communication
|
